Feed SMTI
SM

Sanara MedTech Inc.

SMTI · NASDAQ

$35.17 +0.06% (+$0.02)
1M +2.30%
Market Cap $323.3M
P/E Ratio -
Div. Yield -
ROE 473.55%

Bulios Fair Price

$24.41

30.6% downside

Current Price

$35.17

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SMTI is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
8 /100
Expensive
P/S 2.94x
P/B 40.70x
P/FCF 71.79x
Growth
78 /100
Growing
Book val. growth 47.86%
Rev. growth 31.03%
FCF growth N/A
Profitability
41 /100
Moderate
Net margin 29.15%
Op. margin 9.36%
FCF margin 4.10%
Quality
52 /100
Average
ROE 473.55%
ROA 46.30%
Asset turnover 1.59x
Debt
29 /100
High
Current ratio 2.58x
Int. coverage 0.96x
Net debt/EBITDA 3.50x
Stability
43 /100
Moderate
Rev. volatility 11.53%
EPS volatility 165.23%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SMTI
Online

About the company

Sanara MedTech Inc. is an American company focused on the development, manufacturing, and distribution of medical products for the treatment of chronic wounds and wound infections. Their portfolio includes a wide range of products, including dressings, hydrogels, creams, and other medical preparations that aid in wound healing and minimize the risk of infection. Sanara MedTech focuses on innovative therapeutic approaches and technologies that provide effective and gentle solutions for patients with chronic wounds or wounds caused by injuries or surgical procedures. Their products are designed to provide optimal support for healing and minimize the time needed for patient recovery.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Seth D. Yon

Employees

108

Headquarters

Fort Worth

Upcoming events

11 NOV

Earnings

Upcoming earnings report

50d
29 JUL

Ex-Dividend

Ex-dividend date

310d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.